Omri Amirav-Drory

EarthTraq is building game-changing satellites for simple, secure global positioning.

Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. Our proprietary mechanical system enables efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows. With more than 100 customer sites including the top 10 pharma, researchers use Portal to run high-throughput, physiologically relevant screens and de-risk targets earlier, while cell therapy developers leverage the platform to multi-engineer cells beyond the limits of viral or electroporation methods. Integrated with leading high-throughput robotics and with GMP manufacturing systems, Portal is powering both next-generation discovery and laying the groundwork for future point-of-care cell therapy manufacturing.

Our mission is to cure endometriosis. We are a team of interdisciplinary scientists creating a new model in womens health research centred around an in depth understanding of tissue-level disease processes. We are committed to improving the quality of life of women by providing a new model for therapeutic discovery. We sit at the interface between tissue biology, computation and laboratory disease modelling.

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells. Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

At Powerhouse Biology, we pioneer precision peptide therapeutics to address mitochondrial dysfunction, an underlying driver of many age-related diseases.

We develop therapies to protect the genome.

TwoStep Therapeutics is pioneering a multi-targeting platform to advance a pipeline of targeted therapies that are broadly applicable across solid tumors. With this approach, the company aims to transform cancer treatment by extending precision medicines to more diverse tumor types and patient populations, for which few options exist. TwoStep Therapeutics was co-founded by CEO, Caitlyn Miller, in collaboration with world-renowned academic entrepreneurs at Stanford University: Jennifer Cochran, Ronald Levy, and Nobel Laureate Carolyn Bertozzi. For more information, visit www.twosteptx.com.

Compressing biology to develop the next generation of therapies

Smash the mutants

Helping patients fight treatment-resistant cancer. resistanceBio can discover and overcome clinical treatment resistance pre-clinically.

Pumpkinseed enables life-speed reads of biological bits. We merge the power of silicon photonics and machine learning with state-of-the-art biochemistry for high-resolution protein sequencing. Genomics and transcriptomics have revolutionized how we diagnose and treat disease but it’s only part of the solution. Unraveling the proteome—and characterizing the breadth and dynamics of proteoforms—is critical to address many of the biggest challenges in personal, population, and ecosystem health. Rather than relying on sample amplification or fluorescent tags, we amplify light—and how light interacts in unique ways with each protein. Our method provides high resolution and quantitative insight into proteins, including their sequence, post-translational modifications, structure, and interactions. We strive to enable proactive solutions rather than reactive and crisis-based approaches, informing when to start treatment, which treatment is best, and how to design new therapies and vaccines. Solving the most challenging and impactful problems in medicine and sustainability will require a new lens into the inner working of cells. Come visit us to learn more, or get in contact with us about joining our team to build a better tomorrow with biology.

Talus Bio is making the regulome visible and druggable. We are building the first platform to map, model, and ultimately write the regulome, unlocking thousands of previously undruggable targets, including transcription factors that drive cancer, autoimmunity, and neurodegeneration. Our platform measures the regulome directly in living human cells, generating functional datasets at scale for the first time. These data fuel AI models that learn the logic of genome regulation and predict how to modulate it with precision.

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

La Jolla Labs is a privately held therapeutics company with research in high-throughput screening technology for rare disease drug discovery.

EarthTraq is building game-changing satellites for simple, secure global positioning.

Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. Our proprietary mechanical system enables efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows. With more than 100 customer sites including the top 10 pharma, researchers use Portal to run high-throughput, physiologically relevant screens and de-risk targets earlier, while cell therapy developers leverage the platform to multi-engineer cells beyond the limits of viral or electroporation methods. Integrated with leading high-throughput robotics and with GMP manufacturing systems, Portal is powering both next-generation discovery and laying the groundwork for future point-of-care cell therapy manufacturing.

Our mission is to cure endometriosis. We are a team of interdisciplinary scientists creating a new model in womens health research centred around an in depth understanding of tissue-level disease processes. We are committed to improving the quality of life of women by providing a new model for therapeutic discovery. We sit at the interface between tissue biology, computation and laboratory disease modelling.

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells. Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

At Powerhouse Biology, we pioneer precision peptide therapeutics to address mitochondrial dysfunction, an underlying driver of many age-related diseases.